Trial Profile
TRUDI: A Phase II Study of Neoadjuvant Trastuzumab Deruxtecan and Durvalumab for Stage III, HER2-expressing Inflammatory Breast Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Feb 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Trastuzumab-deruxtecan (Primary)
- Indications Advanced breast cancer; HER2 positive breast cancer; Inflammatory breast cancer
- Focus Therapeutic Use
- Acronyms TRUDI
- 09 Dec 2023 Trial design presented at the 46th Annual San Antonio Breast Cancer Symposium
- 04 May 2023 Status changed from not yet recruiting to recruiting.
- 06 Apr 2023 New trial record